FDA Clears Insilico Medicine's AI-Designed NLRP3 Inhibitor ISM8969 to Enter Phase I for Parkinson's Disease

Insilico Medicine announced on January 23, 2026 that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, had received investigational new drug clearance from the US Food and Drug Administration, intended for the treatment of Parkinson's disease. The planned Phase I trial will evaluate the safety, tolerability and pharmacokinetics of ISM8969 in healthy volunteers and identify the dose levels to recommend for further study. Excessive activation of NLRP3 triggers overproduction of pro-inflammatory cytokines and chemokines, causing sustained inflammation and tissue damage. By inhibiting NLRP3, ISM8969 aims to modulate this inflammation and support neuronal survival and function in patients with neurodegenerative diseases. ISM8969 was discovered and optimised using Chemistry42, Insilico's generative chemistry engine, which is part of its Pharma.AI platform, and was nominated as a preclinical candidate in December 2024. According to the company, it can cross the blood-brain barrier and reach the central nervous system directly, has a balanced druggability profile, and showed efficacy against inflammation in both inflammatory and chronic disease mouse models. "A novel NLRP3 inhibitor, ISM8969 with the desired brain penetrant property made possible via our AI-powered design process, offers the potential to advance Parkinson's Disease treatment to the next generation," said Carol Satler, Senior Vice President for Clinical Development, Non-Oncology, at Insilico Medicine. Insilico has entered a co-development agreement with Hygtia Therapeutics, which receives worldwide rights to research, develop, manufacture and commercialise ISM8969, with each party holding 50% of the global rights; Insilico is eligible for up to $66 million in upfront and milestone payments. Across its programmes, Insilico says it nominated 20 preclinical candidates between 2021 and 2024, taking an average of 12 to 18 months from project start to candidate nomination and synthesising and testing only 60 to 200 molecules per programme, compared with an industry average of about 4.5 years for early-stage discovery.